Total Funding
53
57
Total FundingSeries A raised
Growth Score 53 in past quarter
-2 pts
Heat Score 57 in past quarter
-3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
8702
Axonis Therapeutics is a neuro-focused biotechnology company that focuses on the development of novel neuromedicines.
- Mike Wiecek: Senior Director, Finance & Operations
- Donald Manning: Chief Medical Officer
About the Company
Axonis Therapeutics is a neuro-focused biotechnology company developing medicines targeting KCC2, the critical mediator of inhibition within the brain, by translating breakthrough discoveries from Boston Children’s Hospital, Harvard, and Laval University. It develops a proprietary neuron-specific K-Cl cotransporter (KCC2) discovery engine to
improve the lives of people suffering from neurological disorders by fine-tuning inhibition to treat conditions such as epilepsy, pain, and other central nervous system pathologies.
Women Founded
Women Led
